Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Orphazyme A/S
  6. News
  7. Summary
    ORPHA   DK0060910917

ORPHAZYME A/S

(ORPHA)
  Report
Delayed Quote. Delayed Nasdaq Copenhagen - 08/05 10:59:44 am
27.42 DKK   -5.45%
08/05New publication date for Orphazyme's Interim Report H1 2021
GL
08/05European ADRs Move Higher in Thursday Trading
MT
08/04European ADRs Move Slightly Higher in Wednesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Edge Higher in Wednesday Trading

06/23/2021 | 11:56am EDT


ę MT Newswires 2021
All news about ORPHAZYME A/S
08/05New publication date for Orphazyme's Interim Report H1 2021
GL
08/05European ADRs Move Higher in Thursday Trading
MT
08/04European ADRs Move Slightly Higher in Wednesday Trading
MT
08/03European ADRs Move Higher in Tuesday Trading
MT
08/02ORPHAZYME A/S : ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Orphazyme A/S Investo..
BU
07/22European ADRs Modestly Lower Thursday as Unilever Slides
MT
07/21DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
BU
07/20GLANCY PRONGAY & MURRAY LLP : Reminds Investors of Looming Deadline in the Class..
BU
07/19ORPH SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Orphazyme A/..
BU
07/19CytRx Corporation Announces Closing of $10 Million Offering To Healthcare-Foc..
AQ
More news
Financials
Sales 2021 32,2 M 5,13 M 5,13 M
Net income 2021 -520 M -82,7 M -82,7 M
Net cash 2021 47,9 M 7,61 M 7,61 M
P/E ratio 2021 -2,16x
Yield 2021 -
Capitalization 958 M 153 M 152 M
EV / Sales 2021 28,2x
EV / Sales 2022 4,73x
Nbr of Employees 141
Free-Float 98,6%
Chart ORPHAZYME A/S
Duration : Period :
Orphazyme A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORPHAZYME A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 27,42 DKK
Average target price 81,00 DKK
Spread / Average Target 195%
EPS Revisions
Managers and Directors
Christophe Bourdon Chief Executive Officer
Anders Fink Vadsholt Chief Financial Officer
Georges Gemayel Chairman
Thomas Kirkegaard Jensen Chief Scientific Officer
Claus BornŠs Senior Manager-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ORPHAZYME A/S-59.14%153
BIONTECH SE396.71%100 096
GILEAD SCIENCES, INC.18.85%86 839
WUXI APPTEC CO., LTD.43.36%72 049
REGENERON PHARMACEUTICALS20.25%60 161
VERTEX PHARMACEUTICALS-14.11%51 779